A Peptide Selected by Biopanning Identifies the Integrin αvβ6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer
نویسندگان
چکیده
منابع مشابه
αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease.
Idiopathic pulmonary fibrosis (IPF) and fibrotic nonspecific interstitial pneumonitis are progressive interstitial lung diseases (ILDs) with limited treatment options and poor survival. However, the rate of disease progression is variable, implying there may be different endotypes of disease. We hypothesised that immunophenotyping biopsies from ILD patients might reveal distinct endotypes of pr...
متن کاملPreoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer.
Cytokeratin 19 is particularly abundant in carcinoma of the lung. The CYFRA 21-1 assay has recently been developed for detection of a cytokeratin 19 fragment in serum. In the current study, the prognostic information provided by the CYFRA 21-1 assay in operable nonsmall cell lung cancer (NSCLC) was analysed. Serum levels of CYFRA 21-1 were measured using an immunoradiometric assay (DiaSorin) in...
متن کاملNuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer.
The human Y-box binding protein, YB-1, is a multifunctional protein that regulates gene expression. Nuclear expression of YB-1 has been associated with chemoresistance and poor prognosis of tumour patients. Representative samples from autopsied material of primary tumours from 77 patients with NSCLC were investigated by immunohistochemistry for subcellular distribution of YB-1 and p53, in order...
متن کاملGenome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.
1. Martinalbo J, Bowen D, Camarero J et al. Early market access of cancer drugs in the EU. Ann Oncol 2016; 27: 96–105. 2. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14: 1165––1174. 3. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Onc...
متن کاملNovel peptide–dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer
Phage display technology has been demonstrated to be a powerful tool for screening useful ligands that are capable of specifically binding to biomarkers on the surface of tumor cells. The ligands found by this technique, such as peptides, have been successfully applied in the fields of early cancer diagnostics and chemotherapy. In this study, a novel nonsmall cell lung cancer-targeting peptide ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Research
سال: 2007
ISSN: 0008-5472,1538-7445
DOI: 10.1158/0008-5472.can-07-0245